Parker Waichman Applauds NBC Nightly News Coverage Featuring Firm Client Diane Wirth and Highlighting GLP-1 Vision Loss and NAION

National NBC Nightly News Report Features Parker Waichman Client Diane Wirth and Senior Litigation Counsel Jason S. Goldstein and Brings Further Attention to the Alleged Causal Association Between GLP-1 Medications and Sudden, Permanent Vision Loss

PORT WASHINGTON, N.Y., Sept. 22, 2026 /PRNewswire/ -- Parker Waichman LLP applauds NBC News and NBC Nightly News with Tom Llamas for bringing national attention to the alleged causal association between widely prescribed GLP-1 medications and non-arteritic anterior ischemic optic neuropathy ("NAION"), a serious optic nerve condition that can cause sudden and permanent vision loss.

The NBC Nightly News report, "Hundreds of lawsuits filed against some GLP-1 makers over vision loss," featured Parker Waichman client Diane Wirth, a former nurse practitioner from Georgia who developed NAION and suffered permanent vision loss in her right eye after using Wegovy. Parker Waichman Senior Litigation Counsel Jason S. Goldstein, who serves as Co-Chair of the Plaintiffs' Executive Committee and Federal–State Court Liaison in the federal GLP-1 NAION litigation, MDL No. 3163, was also featured in the report discussing the litigation and concerns surrounding GLP-1 medications and NAION.

Wirth has previously described how she was prescribed Wegovy in February 2025 and later awoke unable to see out of her right eye. The permanent vision loss has affected her ability to work, drive independently and perform ordinary activities of daily living. Wirth has said that had she been warned about the alleged risk of permanent vision loss, she would not have taken the medication.

"Diane's willingness to tell her story on a national platform is extraordinarily important because it puts a human face on what NAION means for patients and their families," said Jason S. Goldstein, Senior Litigation Counsel at Parker Waichman LLP. "The scientific and regulatory evidence concerning the alleged causal association between GLP-1 medications and NAION continues to develop. Patients and physicians deserve clear and complete information about an injury that can strike suddenly, without pain or meaningful warning, and leave a patient with permanent vision loss."

Parker Waichman commends NBC News for examining the developing scientific, regulatory and legal evidence concerning the alleged causal association between GLP-1 medications and NAION and for giving patients such as Wirth an opportunity to describe firsthand the consequences of sudden and irreversible vision loss.

Watch the NBC Nightly News report: "Hundreds of lawsuits filed against some GLP-1 makers over vision loss"

Growing Scientific and Regulatory Attention to GLP-1 Medications and NAION
NAION occurs when blood flow to the optic nerve is disrupted, causing optic nerve damage that can result in partial or complete permanent vision loss. The condition often occurs suddenly and without pain, and there is currently no treatment that reliably restores vision lost as a result of NAION.

GLP-1 receptor agonist medications—including Ozempic, Wegovy, Mounjaro and Zepbound—are prescribed for Type 2 diabetes and/or chronic weight management and have become widely used in the United States.

A growing body of scientific literature and regulatory activity has examined the association between GLP-1 medications and NAION. Plaintiffs allege that manufacturers failed to adequately investigate, disclose and warn patients and prescribing physicians about the risk of NAION and permanent vision loss associated with their medications. The manufacturers dispute plaintiffs' allegations concerning causation and the adequacy of their warnings.

Federal GLP-1 NAION Litigation — MDL No. 3163
Federal lawsuits involving allegations that GLP-1 receptor agonist medications caused NAION have been centralized in MDL No. 3163, In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation, pending before the Honorable Karen S. Marston in the United States District Court for the Eastern District of Pennsylvania.

The multidistrict litigation involves claims concerning widely prescribed GLP-1 medications, including Ozempic, Wegovy, Mounjaro and Zepbound, and allegations that manufacturers failed to adequately warn patients and medical professionals about the risk of NAION and permanent optic nerve injury.

Judge Marston appointed Parker Waichman Senior Litigation Counsel Jason S. Goldstein as Co-Chair of the Plaintiffs' Executive Committee and Federal–State Court Liaison in MDL No. 3163.

Parker Waichman has been actively involved in the developing GLP-1 NAION litigation and represents individuals throughout the United States who allege that they developed NAION and suffered permanent vision loss after using GLP-1 receptor agonist medications.

Parker Waichman LLP Fights for Victims Nationwide
Parker Waichman LLP continues to investigate and file claims on behalf of individuals who suffered serious eye injuries after taking widely prescribed GLP-1 receptor agonist medications.

The Firm is currently accepting cases nationwide involving individuals who suffered vision loss, blindness, NAION or serious optic nerve damage after taking Ozempic, Wegovy, Mounjaro, Zepbound or other GLP-1 medications.

Individuals who suffered these injuries may be entitled to compensation for medical expenses, lost wages, pain and suffering, loss of enjoyment of life and other damages.

Free Case Review for Affected Individuals
If you or a loved one experienced sudden vision loss, blindness, NAION or optic nerve damage after using Ozempic, Wegovy, Mounjaro, Zepbound or another GLP-1 medication, you may have a legal claim against the drug manufacturer. Parker Waichman LLP offers free, no-obligation case evaluations to individuals and families seeking information about their potential legal rights.

For a free case review, call 1-800-YOUR-LAWYER (1-800-968-7529) or visit YourLawyer.com.

About Parker Waichman LLP
Parker Waichman LLP is a national personal injury law firm dedicated to representing individuals and families injured by defective drugs, dangerous medical devices, defective products, environmental exposures, accidents and corporate negligence. Since 1992, the Firm has represented clients in complex personal injury, pharmaceutical, medical device, mass tort and other civil litigation throughout the United States.

Parker Waichman attorneys have held leadership positions in major multidistrict and coordinated litigations throughout the country. The Firm has substantial experience representing individuals who have suffered serious injuries allegedly caused by pharmaceutical products and medical devices, including litigation involving serious and permanent eye injuries.

Parker Waichman LLP has recovered more than $2.4 billion for clients. Prior results do not guarantee a similar outcome. The Firm represents clients nationwide and maintains offices in New York, New Jersey and Florida.

To learn more about Parker Waichman LLP, call 1-800-YOUR-LAWYER (1-800-968-7529) or visit YourLawyer.com.

Media Contact
Jason S. Goldstein, Esq.
Senior Litigation Counsel
Parker Waichman LLP
1-800-968-7529
YourLawyer.com

Attorney Advertising. Prior results do not guarantee a similar outcome.

SOURCE Parker Waichman LLP